Novartis(US:NVS) 智通财经网·2025-04-29 07:03Group 1: Financial Performance - Novartis reported Q1 net sales of $13.2 billion, a 15% year-over-year increase, exceeding analyst expectations of $13.12 billion [1] - Adjusted core operating profit reached $5.58 billion, a 27% increase, significantly above the market expectation of $5.07 billion [1] - The company raised its 2025 full-year net sales growth forecast from mid-single digits to high-single digits, and core operating profit growth from high-single digits to low double digits [1] Group 2: Product Performance - The growth in sales was primarily driven by the heart failure treatment drug Entresto and the arthritis drug Cosentyx [1] - There is a notable increase in market demand for breast cancer treatment drug Kisqali, multiple sclerosis drug Kesimpta, and cholesterol-lowering drug Leqvio [1][2] Group 3: Strategic Initiatives - Facing pressure from generic drug competition, Novartis is accelerating its focus on innovative therapies [2] - The company plans to invest $23 billion in the U.S. over the next five years to establish and expand 10 production sites, ensuring local production of key drugs for the U.S. market [3] - Novartis emphasizes its strategic focus on key markets including the U.S., China, Germany, and Japan [3]